Research

Mayo Clinic is pleased to announce the launch of "Mayo Clinic Proceedings: Innovations, Quality, & Outcomes." An open-access, online medical research journal, "Mayo Clinic Proceedings: Innovations, Quality, & Outcomes" is dedicated to “building upon innovations in research, advancing the quality of medical and surgical care, and promoting optimal patient outcomes.”

This week’s Research Roundup highlights the association of postoperative high-sensitivity troponin levels with myocardial injury and 30-day mortality among patients undergoing noncardiac surgery.

This week’s Research Roundup highlights the comparison of gadolinium concentrations within multiple rat organs after intravenous administration of linear versus macrocyclic gadolinium chelates.

This week’s Research Roundup highlights expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG positive patients.

This week’s Research Roundup highlights the single-nephron glomerular filtration rate in healthy adults.

This week’s Research Roundup highlights noninvasive assessment of renal fibrosis with magnetization transfer MR imaging.

This week’s Research Roundup highlights oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy.

This week’s Research Roundup highlights the evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers.

This week’s Research Roundup highlights the management of diffuse low-grade gliomas in adults.

Researchers at Mayo Clinic have identified a possible cause for a rare infection in heart and lung transplant recipients: the donor.

This week’s Research Roundup highlights how the androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance.

This week’s Research Roundup highlights how AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction.

Some early-stage cancers are missed by conventional screening and are only detected when symptoms occur. Mayo Clinic is collaborating with Grail, a life science company, and Sutter Health of California, on the STRIVE clinical research study to facilitate the development of Grail’s blood tests for early-stage cancer detection.